Gastroenterology Today Summer 2021

More documents

Recommendations

Info

COMPANY NEWS COST EFFECTIVE & USER FRIENDLY SPECIMEN BIO-POUCH UN3373 Compliant Sample Packaging Solution The ShuttlePouch range of leak proof pouches is designed to carry individual 95kPa pressure differential certified blood or urine specimen tubes (or any similar sized specimen tube). They include absorbent material already inside the pouch for convenient compliance to UN3373 packaging requirements. Each leak proof bio-pouch is printed with easy-to-follow instructions showing how to pack and seal the specimen tube. Simply add a rigid outer packaging box for a complete and compliant UN3373 solution. In addition, the 95kPa pressure differential compliant ShuttlePouch is certified for transport by air (IATA). With all the features described above, they can be used with any leak free tube for transport by road or air. The pouches also feature a transparent front so the tube and label are clearly visible. An easy to open tear area facilitates processing when the samples arrive at the lab. ShuttlePouch addresses the needs of customers, radically improving the user experience and reducing the cost of packing and shipping sample tubes compared with using conventional methods. The ShuttlePouch range is exclusive to Alpha Laboratories in the UK and Ireland, and provides a powerful, cost effective solution to the clinical and diagnostic market. Please visit www.alphalabs.co.uk/shuttlepouch for further information or contact Alpha Laboratories on 0800 38 77 32 or email marketing@ alphalabs.co.uk BIOHIT’S TEST PANEL FOR STOMACH HEALTH BACKED BY FURTHER EVIDENCE GASTROENTEROLOGY TODAY - SUMMER 2021 A recent study published by the research group of Professor Francesco Di Mario at Parma University, Italy, found a strong relationship between low levels of plasma Gastrin-17 (G-17) and the manifestation of gastro-oesophageal reflux disease (GORD). 1 These results add to the weight of evidence behind GastroPanel ® , a test produced by BIOHIT Oyj, that includes G-17 as one of three biomarkers used in combination with a Helicobacter pylori IgG assay to distinguish the stomach health of patients with gastrointestinal problems. GastroPanel is designed for the first-line diagnosis of H. pylori infection and atrophic gastritis in patients with dyspepsia or GORD. It is a non-invasive blood test that offers an easy way to check the stomach mucosa and gastric acid secretion in the patient. This can lead to an informed decision of whether further examination is needed – usually by gastroscopy – and ultimately to the early discovery and intervention of gastrointestinal disorders. Current UK guidelines recommend an H. pylori stool antigen test in the care pathway of patients with gastrointestinal problems. However, this test fails to show mucosal damage due to long-term infection, including gastric atrophy (GA) or gastric intestinal metaplasia (GIM), both of which are precursors to cancer. In addition to testing for H. pylori infection, GastroPanel tests for three stomach-specific biomarkers – pepsinogen I, pepsinogen II and G-17 – that provide more information than a stool test alone, helping to non-invasively identify patients at risk. Graham Johnson, Managing Director of BIOHIT HealthCare Ltd, commented: “The results from this study showed that GORD patients both in primary care, and those that had been referred, had statistically significant lower levels of G-17 compared with the dyspeptic patients. 1 This confirms that the G-17 biomarker is a reliable predictor of GORD, and further extends the scope of gastric diseases detectable with the GastroPanel. We hope this helps to implement the wider use of the GastroPanel, which is a proven, cost-effective strategy in screening patients at risk of gastric cancer.” For more information visit www.biohithealthcare.co.uk/gastropanel. About BIOHIT Healthcare Ltd BIOHIT Healthcare Ltd (www.biohithealthcare.co.uk) is part of the Finnish public company, BIOHIT OYJ, which specialises in the development, manufacture and marketing of products and analysis systems for the early diagnosis and prevention of gastrointestinal diseases. The company’s many unique and patented diagnostic tests transform clinical practice and make screening, diagnosis and monitoring of gastrointestinal diseases efficient and cost effective. Non-invasive diagnostics are at the core of BIOHIT’s offering, making it the provider of choice for leading gastroenterologists and laboratory scientists worldwide. References 1. Di Mario F, Crafa P, Franceschi M, et al. Low Levels of Gastrin 17 are Related with Endoscopic Findings of Esophagitis and Typical Symptoms of GERD. JGLD [Internet]. 12Feb.2021 [cited 11May2021];30(1):25-9. Available from: https://www.jgld.ro/jgld/index.php/jgld/article/view/2952 30
COMPANY NEWS POINT-OF-CARE CALPROTECTIN TESTING JUST GOT EASIER WITH NEW AND IMPROVED QUANTUM BLUE ® III To better support timely diagnosis, monitoring and treatment optimisation for IBD patients, the newly improved BÜHLMANN Quantum Blue ® III reader and tests are the perfect inclinic solution. Available exclusively in the UK from Alpha Laboratories Ltd., the calprotectin experts, the system offers simple, rapid lateral flow test technology, with full quantitation and LIMS data connectivity. The tests can easily be performed and read by healthcare personal in the clinic setting during the patient’s appointment. The ability to act on immediate results can improve patient management, save valuable resources and ease patient anxiety that inevitably comes from delay. The Quantum Blue reader is a small, dedicated bench top instrument offering touch screen or optional bar code data entry. Results can be directly transferred to your data system, printed or downloaded to USB. For faecal or serum calprotectin assays, results are available in just 15 minutes. Tests for monitoring serum trough levels of the biologic drugs Infliximab and Adalimumab and their anti-drug antibodies are also available, giving results in one hour. Please visit www.calprotectin.co.uk for further information or contact Alpha Laboratories on 0800 38 77 32 or email marketing@alphalabs.co.uk POSTER SUBMISSIONS If you have submitted a poster to previous BSG or ENDOLIVE events and would like it published in Gastroenterology Today please forward a PDF of your poster to the email address listed below. Material submitted will be seen by those working within all UK gastroenterology departments and endoscopy units. All submissions should be forwarded to info@mediapublishingcompany.com If you have any queries please contact the publisher Terry Gardner via: info@mediapublishingcompany.com GASTROENTEROLOGY TODAY - SUMMER 2021 31
Page 1 and 2: Volume 31 No. 2 Summer 2021 Gastroe
Page 3 and 4: CONTENTS CONTENTS Gastroenterology
Page 5 and 6: WITH YOUR HELP We’ve made Gastroe
Page 7 and 8: FEATURE simple, easy to use, hygien
Page 9 and 10: FEATURE How can you reduce the risk
Page 11 and 12: IDENTIFYING ATROPHIC GASTRITIS WITH
Page 13 and 14: Optimising maintenance therapy for
Page 15 and 16: FEATURE Study design and study popu
Page 17 and 18: FEATURE The criterion “registrati
Page 19 and 20: FEATURE GASTROENTEROLOGY TODAY - SU
Page 21 and 22: CASE REPORT of toxicity. Clinical m
Page 23 and 24: CASE REPORT Table 1 Summary of pati
Page 25 and 26: CASE REPORT The mechanism of inflix
Page 27 and 28: NEWS were assessed for how they had
Page 29: NEWS addition, we host a dedicated

Gastroenterology Today Summer 2021

Create successful ePaper yourself

Delete template?

Save as template?